Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimal residual disease.

T Lion1

  • 1Children's Cancer Research Institute, St. Anna Children's Hospital, Vienna, Austria. Lion@CCRI.univie.ac.at

Current Opinion in Hematology
|November 5, 1999
PubMed
Summary
This summary is machine-generated.

Monitoring minimal residual disease in hematologic malignancies aids treatment assessment and relapse risk evaluation. Sensitive techniques reveal that persistent disease doesn't always mean relapse, guiding clinical decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Leukemia·2020
Same author

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Leukemia·2019
Same author

Klebsiella pneumoniae prevents spore germination and hyphal development of Aspergillus species.

Scientific reports·2019
Same author

Comparison of different approaches to quantitative adenovirus detection in stool specimens of hematopoietic stem cell transplant recipients.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2016
Same author

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.

Leukemia·2016
Same author

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Leukemia·2016
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Background:

  • Minimal residual disease (MRD) monitoring is crucial for hematologic malignancies.
  • Assessing treatment response and relapse risk is vital for patient management.

Purpose of the Study:

  • To highlight the prognostic relevance of MRD monitoring in hematologic disorders.
  • To emphasize the role of sensitive techniques in identifying and quantifying residual disease.

Main Methods:

  • Utilizing sensitive molecular techniques to detect tumor cells amidst normal cells.
  • Quantitative assessment of persisting neoplastic cells.

Main Results:

  • The presence of residual disease at high levels does not invariably predict relapse.

Related Experiment Videos

  • Quantitative MRD surveillance provides prognostically relevant information.

    • Conclusions:

    • MRD monitoring offers valuable insights into treatment sensitivity and tumor biology.
    • Quantitative MRD assessment aids clinical decision-making in leukemia management.